Nasal Polyps, Severe Eosinophilic Asthma
Conditions
Keywords
Severe Eosinophilic Asthma, nasal polyps, benralizumab, FASENRA.
Brief summary
The purpose of this observational study is to describe the population of patients with SEA + NP who have been prescribed FASENRA and assess available clinical outcomes for both NP and asthma.
Detailed description
In light of the increasing importance of comorbidities in driving choice for biologics in severe asthma there is a knowledge gap to understand SEA patients with comorbid NP for whom the decision to start biologics was based on the presence of severe, uncontrolled asthma. This retrospective, observational study will describe the population of patients with SEA + NP who have been prescribed FASENRA and assess available clinical outcomes for both NP and asthma.
Interventions
OTHERFASENRA(benralizumab)
This is a retrospective, observational study with secondary data collection utilizing medical chart review in hospitals or clinical centres that treated SEA + NP patients with benralizumab. Patient data including demographics, clinical characteristics, medication history, biologic treatment, and NP and asthma clinical outcomes will be abstracted from patient medical charts onto a pre-approved electronic case report form. No personal identifiable data will be collected. Data from all participating centres will be combined into a single anonymised dataset for analysis.
Sponsors
AstraZeneca
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
1. Current or previous treatment with benralizumab for SEA 2. Physician-confirmed diagnosis and evaluation of NP using NPS and/or SNOT-22 before and after first benralizumab injection 3. Patients who have follow-up period of at least 5 months from first benralizumab injection or at least 4 consecutive injections of benralizumab 4. Able to provide signed informed consent (if required based on local guidelines)
Exclusion criteria
1. Patient on any other biologic during the 12 months prior to treatment with benralizumab 2. Previously or currently receiving any biologics for the treatment of asthma or NP in a clinical trial. This
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Baseline demographics, clinical characteristics, and background treatments, as well as PROs for asthma control and HRQoL, asthma exacerbation, and healthcare resource utilization. | At or up to 12 months prior to first benralizumab dose. | To describe baseline demographics, clinical characteristics, and background treatments, as well as PROs (patient-reported outcomes) for asthma control and HRQoL(health-related quality of life), asthma exacerbation, and healthcare resource utilization. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| SNOT-22 total score | Up to 12 months prior to and up to 12 months from first benralizumab dose. | To describe the distribution (mean, median, range) of NP patient reported HRQoL total score (SNOT-22\[Sino-nasal Outcome Test-22\]) before and after initiation of benralizumab among EA+NP patients. SNOT-22 measures physical problems, functional limitations, and emotional consequences of sino-nasal conditions. SNOT-22 total score is calculated as the sum of all 22 responses and range from 0 to 110 (higher scores indicate poorer HRQoL). |
| Overall SCS use. SCS use for asthma only. SCS use for NP only | Up to 12 months from first benralizumab dose. | To describe the use of SCS (systemic corticosteroids) after initiation of benralizumab among SEA + NP patients |
| Asthma Clinical outcomes. | Up to 12 months from first benralizumab dose. | To describe asthma exacerbations, PROs, lung function, and benralizumab treatment patterns. |
| NP surgery type and/or procedure | Up to 12 months from first benralizumab dose. | Proportion of patients with different type of surgery and/or procedure |
| Repeated or revision surgery for NP | Up to 12 months from first benralizumab dose. | Proportion of patients with repeated or revision surgery |
| Time to NP surgery | Up to 12 months from first benralizumab dose. | Timing (in days) from first benralizumab dose to NP surgery and/or repeated/revision surgery |
| NP surgery complications | Up to 12 months from first benralizumab dose. | Proportion of patients with minor and major surgical complication. |
| Total NPS | Up to 12 months prior to and up to 12 months from first benralizumab dose. | To describe the distribution (mean, median, range) of NPS (nasal polyp score) before and after initiation of benralizumab among SEA (severe eosinophilic asthma) +NP (nasal polyps) patient. NPS is the sum of the left and the right nostril scores evaluated by nasal endoscopy. Total score ranges from 0 to 8, with higher scores indicate larger-sized polyps. |
Other
| Measure | Time frame | Description |
|---|---|---|
| All-cause healthcare resource utilization | Up to 12 months from first benralizumab dose. | To describe all-cause healthcare resources utilization. |
| Asthma-related healthcare resources utilization | Up to 12 months from first benralizumab dose. | To describe asthma-related healthcare resources utilization. |
| NPS by subgroups | Up to 12 months prior to and up to 12 months from first benzelizumab dose. | To describe the distribution (mean, median) of NPS among subgroups of patients with different characteristics: demographics, clinical characteristics, and asthma clinical outcomes (number of exacerbations). NPS is the the sum of left and right nostril scores evaluated by nasal endoscopy. Total score ranges from 0 to 8, with higher scores indicate larger-sized polyps. |
| SNOT-22 total score by subgroups | Up to 12 months prior to and up to 12 months from first benralizumab dose. | To describe the distribution (mean, median) of SNOT-22 total scores among subgroups of patients with different characteristics : demographics, clinical characteristics, and asthma clinical outcomes (number of exacerbations). SNOT-22 measures physical problems, functional limitations, and emotional consequences of sino-nasal conditions. SNOT-22 total score is calculated as the sum of all 22 responses and range from 0 to 110 (higher scores indicate poorer HRQoL). |
| NP medications | Up to 12 months from first benralizumab dose. | To describe NP medications. |
| Asthma medications | Up to 12 months from first benralizumab dose. | To describe asthma medications. |
Countries
France, Germany, Italy, Japan, Spain, United States
Outcome results
None listed